Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
| Current Price | ₹1,429.20 |
|---|---|
| Market Cap | ₹83,008 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 23.7 |
| Return on Equity | 9.93% |
| 52-Week Range | ₹1,016.10 – ₹1,550.00 |
| Beta (1Y) | 0.25 |
| Dividend Yield | 0.00% |
1. Pharmaceutical Products-100%
Aurobindo Pharma Ltd. is trading at ₹1,429.20, with a market capitalisation of ₹83,008 Cr.
Aurobindo Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Aurobindo Pharma Ltd. has a P/E of 23.7 and a return on equity of 9.93%.